Internal Medicine Alert – June 15, 2005
June 15, 2005
View Issues
-
Esomeprazole in Patients with Upper GI Symptoms Taking NSAIDs, Including COX-2 Inhibitors
Esomeprazole 20 mg and 40 mg daily improve upper GI symptoms occurring during NSAID therapy, including selective COX-2 inhibitors. -
Folate: An Under-Rated Vitamin!
Increased intake of folate in any form is associated with a reduced risk of developing hypertension for women. -
Is Long-Term Alendronate Treatment a Problem?
This study emphasizes the need for increased awareness and monitoring for the potential development of excessive suppression of bone turnover during long-term alendronate therapy. -
Pharmacology Update: Exenatide Injection (ByettaTM)
The first of a new class of antidiabetic drugs has been approved for the treatment of type 2 diabetes mellitus. -
Clinical Briefs
Because many of the clinical consequences of hemochromatosis are able to be reversed, or at least halted by appropriate treatment (phlebotomy), it is important to heighten clinician awareness of the disorder. -
ECG Review: Too Irregular for VT?
The lead II rhythm strip shown in the Figure was obtained from an older man with ischemic cardiomyopathy. This asymptomatic 10-beat run of anomalous complexes was felt to be too irregular for VT (ventricular tachycardia). Do you agree? -
Pharmacology Watch: Is Nesiritide Associated with a Higher Death Rate?
Nesiritide, Scios' intravenous recombinant form of human B-type naturetic peptide, has been widely used for the treatment of congestive heart failure in hospitalized patients. That may change with the publication of a new study that suggests that patients with acutely decompensated heart failure treated with nesiritide have a higher death rate at 30 days compared with patients who are not treated with the drug.